Systemic mastocytosis

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 419-432

  Akin, Cem ^a   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Bone marrow; C kit; Mast cells; Urticaria pigmentosa

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CLADRIBINE; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; IMATINIB; STEM CELL FACTOR; TRYPTASE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ASCITES; BONE MARROW; CELL ACTIVATION; CELL INFILTRATION; CELL STRUCTURE; CELL SURFACE; CLINICAL FEATURE; CODON; CYTOLOGY; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER; MAST CELL; MOLECULAR BIOLOGY; PALLIATIVE THERAPY; PATIENT; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PRURITUS; REVIEW; SKIN; SKIN BIOPSY; SPLEEN; STEM CELL; STRUCTURE ANALYSIS; SYMPTOM; SYSTEMIC MASTOCYTOSIS;

ADULT; CHILD; HUMANS; MASTOCYTOSIS, SYSTEMIC;

EID: 1542329011     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.103822     Document Type: Review

References (56)

1. Nettleship E, Tay W. 1869. Rare forms of urticaria. BMJ 2:323
2. Carter MC, Metcalfe DD. 2002. Paediatric mastocytosis. Arch. Dis. Child 86:315-19
3. Kettelhut BV, Metcalfe DD. 1991. Pediatric mastocytosis. J. Invest. Dermatol. 96:15S-18S
4. Sondergaard J, Asbo-Hansen E. 1987. Mastocytosis in childhood. In Pediatric Dermatology, ed. R Happle, pp. 148-54. Berlin: Springer-Verlag
5. Soter NA. 1991. The skin in mastocytosis. J. Invest. Dermatol. 96:32S-38S; discussion 8S-9S
6. Wolff K, Komar M, Petzelbauer P. 2001. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk. Res. 25: 519-28
7. Garriga MM, Friedman MM, Metcalfe DD. 1988. A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J. Allergy Clin. Immunol. 82:425-32
8. Brockow K, Akin C, Huber M, et al. 2002. Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase. J. Allergy Clin. Immunol. 109:82-88
9. Brockow K, Akin C, Huber M, et al. 2003. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J. Am. Acad. Dermatol. 48:508-16
10. Golitz LE, Weston WL, Lane AT. 1984. Bullous mastocytosis: diffuse cutaneous mastocytosis with extensive blisters mimicking scalded skin syndrome or erythema multiforme. Pediatr. Dermatol. 1:288-94
11. Chagrin L, Sachs P. 1954. Urticaria pigmentosa appearing as a solitary nodular lesion. Arch. Dermatol. Syphilol. 69:345-55
12. Findlay GH, Schulz EJ, Pepler WJ. 1960. Diffuse cutaneous mastocytosis. S. Afr. Med. J. 34:353
13. Parkes Weber F, Rast H. 1930. Telangiectasia macularis eruptiva perstans. Br. J. Dermatol. Syph. 42:374-82
14. Walls AF, Jones DB, Williams JH, et al. 1990. Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J. Pathol. 162:119-26
15. Li WV, Kapadia SB, Sonmez-Alpan E, et al. 1996. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod. Pathol. 9:982-88
16. Horny HP, Sillaber C, Menke D, et al. 1998. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 22:1132-40
17. Furitsu T, Tsujimura T, Tono T, et al. 1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736-44
18. Nagata H, Worobec AS, Oh CK, et al. 1995. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92:10560-64
19. Schwartz LB, Sakai K, Bradford TR, et al. 1995. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Invest. 96:2702-10
20. Akin C, Schwartz LB, Kitoh T, et al. 2000. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 96:1267-73
21. Escribano L, Orfao A, Diaz-Agustin B, et al. 1998. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 91:2731-36
22. Valent P, Horny H, Escribano L, et al. 2001. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 25:603-25
23. Valent P, Horny HP, Li CY, et al. 2001. Mastocytosis. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues, ed. ES Jaffe, NL Harris, H Stein, JW Vardiman, pp. 291-302. Lyon: IARC Press
24. Parker RI. 1991. Hematologic aspects of mastocytosis. I. Bone marrow pathology in adult and pediatric systemic mast cell disease. J. Invest. Dermatol. 96:47S-51S
25. Horny HP, Kaiserling E. 1988. Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: a histological and immunohistological study. Br. J. Haematol. 69:449-55
26. Akin C, Jaffe ES, Raffeld M, et al. 2002. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells. Am. J. Clin. Pathol. 118:242-47
27. Sperr WR, Escribano L, Jordan JH, et al. 2001. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 25:529-36
28. Klion AD, Noel P, Akin C, et al. 2003. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:4660-66
29. Schwartz LB. 2001. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk. Res. 25:553-62
30. Sperr WR, Jordan JH, Stehberger B, et al. 1999. Detection of elevated serum tryptase levels in MDS. Blood 94:287b
31. Sperr WR, Jordan JH, Baghestanian M, et al. 2001. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 98:2200-9
32. Longley BJ, Tyrrell L, Lu SZ, et al. 1996. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:312-14
33. Longley BJ Jr, Metcalfe DD, Tharp M, et al. 1999. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA 96:1609-14
34. Akin C, Kirshenbaum AS, Semere T, et al. 2000. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 28:140-47
35. Jordan J, Fritsche-Polanz R, Sperr WR, et al. 2001. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk. Res. 25:627-34
36. Akin C, Scott LM, Metcalfe DD. 2001. Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case? Leuk. Res. 25:635-38
37. Valent P, Akin C, Sperr WR, et al. 2002. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int. Arch. Allergy Immunol. 127:137-39
38. Worobec AS. 2000. Treatment of systemic mast cell disorders. Hematol. Oncol. Clin. North Am. 14:659-87, vii
39. Escribano L, Akin C, Castells M, et al. 2002. Mastocytosis: current concepts in diagnosis and treatment. Ann. Hematol. 81:677-90
40. Soter NA, Austen KF, Wasserman SI. 1979. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 301:465-69
41. Horan RF, Sheffer AL, Austen KF. 1990. Cromolyn sodium in the management of systemic mastocytosis. J. Allergy Clin. Immunol. 85:852-55
42. Czarnetzki BM, Rosenbach T, Kolde G, et al. 1985. Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. Arch. Dermatol. Res. 277:105-13
43. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. 1992. Response to interferon alfa-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 326:619-23
44. Valent P, Akin C, Sperr WR, et al. 2003. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk. Res. 27:635-41
45. Worobec AS, Kirshenbaum AS, Schwartz LB, et al. 1996. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk. Lymphoma 22:501-8
46. Tefferi A, Li CY, Butterfield JH, et al. 2001. Treatment of systemic mast-cell disease with cladribine. N. Engl. J. Med. 344:307-9
47. Ronnov-Jessen D, Lovgreen Nielsen P, Horn T. 1991. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 8:413-15
48. Fodinger M, Fritsch G, Winkler K, et al. 1994. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 84:2954-59
49. Przepiorka D, Giralt S, Khouri I, et al. 1998. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am. J. Hematol. 57:24-28
50. Nakamura R, Akin C, Bahceci E, et al. 2002. Allogeneic non-myeloablative stem cell transplantation for advanced systemic mastocytosis: possible induction of a graft-versus mastocytosis effect. Biol. Blood Marrow Transplant. 8:81 (Abstr.)
51. Buchdunger E, Zimmermann J, Mett H, et al. 1996. Inhibition of the Ab1 protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:100-4
52. Druker BJ, Tamura S, Buchdunger E, et al. 1996. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nature Med. 2:561-66
53. Buchdunger E, Cioffi CL, Law N, et al. 2000. Ab1 protein-tyro sine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:139-45
54. Ma Y, Zeng S, Metcalfe DD, et al. 2002. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-44
55. Zermati Y, De Sepulveda P, Feger F, et al. 2003. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22:660-64
56. Akin C, Brockow K, D'Ambrosio C, et al. 2003. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp. Hematol. 31:686-92